

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
 Stylesheet Version v1.2

EPAS ID: PAT8044442

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT	
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT	
<b>CONVEYING PARTY DATA</b>		
	<b>Name</b>	<b>Execution Date</b>
	MAGENTA THERAPEUTICS, INC.	04/14/2023
<b>RECEIVING PARTY DATA</b>		
<b>Name:</b>	HEIDELBERG PHARMA RESEARCH GMBH	
<b>Street Address:</b>	GREGOR-MENDEL-STRASSE 22	
<b>City:</b>	LADENBURG	
<b>State/Country:</b>	GERMANY	
<b>Postal Code:</b>	68526	
<b>PROPERTY NUMBERS Total: 7</b>		
<b>Property Type</b>	<b>Number</b>	
<b>Patent Number:</b>	10576161	
<b>Patent Number:</b>	10434185	
<b>Application Number:</b>	16198407	
<b>Application Number:</b>	17155936	
<b>Application Number:</b>	17244721	
<b>Application Number:</b>	17155832	
<b>Application Number:</b>	17457607	
<b>CORRESPONDENCE DATA</b>		
<b>Fax Number:</b>		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
<b>Phone:</b>	571-458-7790	
<b>Email:</b>	ma@gandmpatent.com	
<b>Correspondent Name:</b>	GRUNEBERG AND MYERS PLLC	
<b>Address Line 1:</b>	1775 TYSONS BLVD	
<b>Address Line 2:</b>	5TH FLOOR	
<b>Address Line 4:</b>	TYSONS, VIRGINIA 22102	
<b>ATTORNEY DOCKET NUMBER:</b>	005425USCO	
<b>NAME OF SUBMITTER:</b>	MALIKA ASH SHAKUR	
<b>SIGNATURE:</b>	/Malika Ash Shakur/	
<b>DATE SIGNED:</b>	07/07/2023	

PATENT

**Total Attachments: 13**

source=005425USCO\_Assignment-Magenta to HPRG#page1.tif  
source=005425USCO\_Assignment-Magenta to HPRG#page2.tif  
source=005425USCO\_Assignment-Magenta to HPRG#page3.tif  
source=005425USCO\_Assignment-Magenta to HPRG#page4.tif  
source=005425USCO\_Assignment-Magenta to HPRG#page5.tif  
source=005425USCO\_Assignment-Magenta to HPRG#page6.tif  
source=005425USCO\_Assignment-Magenta to HPRG#page7.tif  
source=005425USCO\_Assignment-Magenta to HPRG#page8.tif  
source=005425USCO\_Assignment-Magenta to HPRG#page9.tif  
source=005425USCO\_Assignment-Magenta to HPRG#page10.tif  
source=005425USCO\_Assignment-Magenta to HPRG#page11.tif  
source=005425USCO\_Assignment-Magenta to HPRG#page12.tif  
source=005425USCO\_Assignment-Magenta to HPRG#page13.tif

## ASSIGNMENT

This **PATENT ASSIGNMENT** is made as of the date specified below by and between **Magenta Therapeutics, Inc.**, a Delaware corporation with principal offices located at 100 Technology Square (5th Floor), Cambridge, MA 02139, USA ("Assignor"), and **Heidelberg Pharma Research GmbH**, a corporation organized under the laws of Germany and doing business at Gregor-Mendel-Strasse 22, 68526 Ladenburg, Germany ("Assignee").

**WHEREAS**, in connection with the termination of the Exclusive Research, Development Option and License Agreement dated March 1, 2018, as amended, between Magenta and HDPR, Magenta wishes to assign to HDPR, and HDPR wishes to acquire and accept, certain patent rights and patent applications as described herein, subject to the terms and conditions of this Patent Assignment

1. **NOW, THEREFORE**, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the undersigned parties agree as follows: Assignor does hereby sell, assign, transfer, convey and deliver unto the Assignee the entire right, title and interest in and to the invention described and claimed in Schedule A attached hereto (the "Assigned Patents and Patent Applications" as defined below), and Assignee hereby ratifies, acquires and confirms the assumption and acceptance of, all of Assignor's worldwide right, title, and interest in and to: (a) such Assigned Patents and Patent Applications, together with all registrations and applications for the foregoing; and all rights to request, apply for, file and register patent rights in any of the foregoing; (b) all applications, including provisional applications, continuation applications, divisional applications, substitute applications and continuation-in-part applications claiming the benefit of the filing date of or priority to the foregoing; all patents of addition of the foregoing; all continued examinations, re-examinations, *inter partes* review and post-grant review certificates of the foregoing; (c) all validations, supplementary protection certifications and extensions of the foregoing; (d) all inventions disclosed or claimed by any of the foregoing; (e) all rights to claim priority to the foregoing under the International Convention for the Protection of Industrial Property, the Patent Cooperation Treaty, and applicable bilateral or multilateral treaties; (f) all patents issuing from the foregoing and all amendments, reissues, and extensions of the foregoing; (g) all defenses relating to or arising from any of the foregoing, and all rights of actions arising from the foregoing, including without limitation all claims for damages by reason of infringement or violation of the foregoing and all present, past and future rights to sue and collect damages or seek injunctive relief for any such infringement or violation of the foregoing; and (h) all income, royalties and any other payments now and hereafter due and/or payable to in respect of the foregoing, in each case, to be held and enjoyed by Assignee for its own use and benefit and for its successors legal representatives and assigns as the same would have been held as fully and entirely by Assignor had this assignment not been made (collectively, the "Assigned Patent and Patent Application Rights").

2. Assignor hereby confirms that, at the time of invention, except for any rights, titles and/or interests that have arisen to Assignee under law or that had already been transferred to Assignee, ownership of the entire right, title, and interest in and to the said Assigned Patents and Patent Applications were conveyed to Assignor, and that the Assignor was unencumbered and had good and full right and lawful authority to convey the same to Assignee.

Assignment A Magenta / HDPR	Page 1 of 13 v. 1.2 Apr 12 2023
WBD (US) 61201731v1	



3. To the extent that any of its rights to the Assigned Patents and Patent Applications were not assigned, Assignor hereby assigns all of its right, title and interest in and to the Assigned Patent and Patent Applications to the Assignee, including the Assigned Patent and Patent Application Rights.

4. Assignor shall promptly execute and deliver such documents, and do and perform such acts and things as Assignee, its successors, legal representatives and/or assigns may reasonably request to give effect to, document and record, perfect and enforce the assignment of the Assigned Patent and Patent Application Rights herein recited, including without limitation executing and delivering such other documents as may be required to give full effect to and to perfect the rights of Assignee, its successors, legal representatives and assigns under this Patent Assignment in and to the Assigned Patent and Patent Application Rights worldwide.


5. Assignor further agrees, at any time, upon the reasonable request of Assignee, its successors, legal representatives and/or assigns, to execute and deliver same, any additional applications for patent arising from or relating to the Assigned Patent and Patent Application Rights, or any part or parts thereof, including without limitation any provisional, utility, design, continuation, continuation-in-part, divisional, reissue, substitute, and extension application(s) to the foregoing; and all re-examination, inter partes, post-grant and opposition certification(s) or amendments or reissues of the foregoing and all patent application(s) claiming benefit of or priority from the foregoing; and all patents issued from the foregoing. Assignor further confirms that Assignor has not made any agreement in conflict with this Patent Assignment.

6. Assignor hereby grants Assignee the power to insert on this assignment any further identification which may be necessary or desirable in order to comply with the rules of the appropriate governmental agencies, including the United States Patent and Trademark office for recordation of this document, and to provide Assignee with the necessary authority and powers of attorney to prosecute and maintain pending applications and patents included in the Assigned Patent and Patent Application Rights. In furtherance thereof, Assignor agrees to execute and deliver to Assignee the Assignment of Patents in the form attached hereto as Schedule B (the "Form of Assignment of Patents").

7. Assignor represents and warrants to Assignee that (i) Assignor is the sole owner of all right, title, and interest in and to the Assigned Patent and Patent Application Rights, and said rights are good and valid, (ii) Assignor has not assigned, licensed, or otherwise transferred or agreed to transfer any right, title, or interest in the Assigned Patent and Patent Application Rights to anyone other than Assignee, (iii) the Assigned Patent and Patent Application Rights are free and clear of any and all liens, encumbrances, claims, or security interest(s), to the extent such right, title, and interest exist, before the Effective Date of this Patent Assignment, (iv) that there are no claims, lawsuits, or other proceedings, pending or threatened that involve or relate to the Assigned Patent and Patent Application Rights, and (v) upon the execution of this Patent Assignment, Assignee will have good and valid title to the entirety of the Assigned Patent and Patent Application Rights.

8. This Patent Assignment shall be binding upon and inure to the benefit of the parties hereto and their respective successors, legal representatives and assigns. As between the parties, this Patent Assignment and any claim, controversy, dispute or cause of action (whether in contract, tort or otherwise) based upon, arising out of or relating to this Patent Assignment shall be governed by and

Assignment A Magenta / HDPR	Page 2 of 13 v. 1.2 Apr. 12 2023
WBD (US) 61201731v1	




construed in accordance with the internal laws of the Commonwealth of Massachusetts applicable to agreements made and to be performed entirely within the Commonwealth of Massachusetts, without regard to the conflicts of laws principles thereof.

9. This Patent Assignment may be executed in the original in any number of counterparts, each of which shall be deemed to be an original and all of which together shall constitute one and the same instrument.

Assignment A  
Magenta / HDPR  
WBD (US) 61201731v1

Page 3 of 13  
v. 1.2  
Apr. 12 2023



**PATENT**  
**REEL: 064178 FRAME: 0216**


The undersigned parties, by their authorized representatives, have executed this Patent Assignment effective as of the date executed below:

As read and agreed to by:

**Magenta Therapeutics, Inc.**

("Assignor")

By:



(Signature)

Thomas Beetham

(Print Name)


Chief Legal Officer

Title

Date:

14 April 2023

Witness:





Date:

14 April 2023

Witness:

Date:




14/4/23  Commissioner  
exp. 1/28/28

Heidelberg Pharma Research GmbH

("Assignee")

By:



(Signature)

Dr. Jan Schmidt-Brand

Chief Executive Officer


(Print Name)

Title

Date:

17. April 2023

Witness:



Date:

17 April 2023

Witness:

Date:

**Schedule A (Assigned Patents and Patent Applications)**

Country	Application No.	Filing Date	Title
AR	P20180100135	January 19, 2018	COMPOSITIONS AND METHODS FOR THE DEPLETION OF CD137+ CELLS
AU	2018209452	July 2, 2019	COMPOSITIONS AND METHODS FOR THE DEPLETION OF CD137+ CELLS
BR	BR1120190149910	July 19, 2019	COMPOSITIONS AND METHODS FOR THE DEPLETION OF CD137+ CELLS
CA	3,049,501	July 5, 2019	COMPOSITIONS AND METHODS FOR THE DEPLETION OF CD137+ CELLS
CN	201880019999.0	September 20, 2019	COMPOSITIONS AND METHODS FOR THE DEPLETION OF CD137+ CELLS
EA	201991408	July 8, 2019	COMPOSITIONS AND METHODS FOR THE DEPLETION OF CD137+ CELLS
EP	18741244.0	July 18, 2019	COMPOSITIONS AND METHODS FOR THE DEPLETION OF CD137+ CELLS
HK	62020006838.0	May 1, 2020	COMPOSITIONS AND METHODS FOR THE DEPLETION OF CD137+ CELLS
IL	268058	July 15, 2019	COMPOSITIONS AND METHODS FOR THE DEPLETION OF CD137+ CELLS
IN	201917032566	August 12, 2019	COMPOSITIONS AND METHODS FOR THE DEPLETION OF CD137+ CELLS
JP	2019-539200	July 19, 2019	COMPOSITIONS AND METHODS FOR THE DEPLETION OF CD137+ CELLS
JP	2023-057988	March 31, 2023	COMPOSITIONS AND METHODS FOR THE DEPLETION OF CD137+ CELLS
KR	10-2019-7023935	August 14, 2019	COMPOSITIONS AND METHODS FOR THE DEPLETION OF CD137+ CELLS
MX	MX/A/2019/008205	July 8, 2019	COMPOSITIONS AND METHODS FOR THE DEPLETION OF CD137+ CELLS

Assignment A  
Magenta / HDPR

WBD (US) 61261731v1

Page 6 of 13  
v. 1.2  
Apr. 12 2023



Country	Application No.	Filing Date	Title
Country	Application No.	Filing Date	Title
MX	MX/a/2022/011546	September 14, 2022	COMPOSITIONS AND METHODS FOR THE DEPLETION OF CD137+ CELLS
SG	11201906319X	July 8, 2019	COMPOSITIONS AND METHODS FOR THE DEPLETION OF CD137+ CELLS
SG	10202102897P	March 22, 2021	COMPOSITIONS AND METHODS FOR THE DEPLETION OF CD137+ CELLS
TW	107102127	January 19, 2018	COMPOSITIONS AND METHODS FOR THE DEPLETION OF CD137+ CELLS
US	15/875,793	January 19, 2018	COMPOSITIONS AND METHODS FOR THE DEPLETION OF CD137+ CELLS
US	62/448,741	January 20, 2017	COMPOSITIONS AND METHODS FOR THE DEPLETION OF CD137+ CELLS
US	62/595,977	December 7, 2017	COMPOSITIONS AND METHODS FOR THE DEPLETION OF CD137+ CELLS
US	16/198,407	November 21, 2018	COMPOSITIONS AND METHODS FOR THE DEPLETION OF CD137+ CELLS
US	16/748,496	January 21, 2020	COMPOSITIONS AND METHODS FOR THE DEPLETION OF CD137+ CELLS
WO	PCT/IB2018/050365	January 19, 2018	COMPOSITIONS AND METHODS FOR THE DEPLETION OF CD137+ CELLS
ZA	2019/04471	July 8, 2019	COMPOSITIONS AND METHODS FOR THE DEPLETION OF CD137+ CELLS



Country	Application No.	Filing Date	Title
AU	2019312200	January 28, 2021	USE OF ANTI-CD137 ANTIBODY DRUG CONJUGATE (ADC) IN ALLOGENEIC CELL THERAPY
CA	3,107,019	January 19, 2021	USE OF ANTI-CD137 ANTIBODY DRUG CONJUGATE (ADC) IN ALLOGENEIC CELL THERAPY
CN	201980061612.2	March 19, 2021	USE OF ANTI-CD137 ANTIBODY DRUG CONJUGATE (ADC) IN ALLOGENEIC CELL THERAPY
EP	19842193.5	February 18, 2021	USE OF ANTI-CD137 ANTIBODY DRUG CONJUGATE (ADC) IN ALLOGENEIC CELL THERAPY
HK	62021043128.9	November 25, 2021	USE OF ANTI-CD137 ANTIBODY DRUG CONJUGATE (ADC) IN ALLOGENEIC CELL THERAPY
JP	2021-503599	January 21, 2021	USE OF ANTI-CD137 ANTIBODY DRUG CONJUGATE (ADC) IN ALLOGENEIC CELL THERAPY
US	17/155,936	January 22, 2021	USE OF ANTI-CD137 ANTIBODY DRUG CONJUGATE (ADC) IN ALLOGENEIC CELL THERAPY
US	62/702,292	July 23, 2018	USE OF ANTI-CD137 ANTIBODY DRUG CONJUGATE (ADC) IN ALLOGENEIC CELL THERAPY
WO	PCT/US2019/043119	July 23, 2019	USE OF ANTI-CD137 ANTIBODY DRUG CONJUGATE (ADC) IN ALLOGENEIC CELL THERAPY




Assignment A Magenta / HDPR WBD (US) 61201731v1	Page 8 of 13 v. 1.2 Apr. 12 2023
---	--

Country	Application No.	Filing Date	Title
AU	2018374283	May 18, 2020	COMPOSITIONS AND METHODS FOR THE DEPLETION OF CD5+ CELLS
BR	BR1120200106623	May 27, 2020	COMPOSITIONS AND METHODS FOR THE DEPLETION OF CD5+ CELLS
CA	3082310	May 8, 2020	COMPOSITIONS AND METHODS FOR THE DEPLETION OF CD5+ CELLS
CN	201880088141.X	July 29, 2020	COMPOSITIONS AND METHODS FOR THE DEPLETION OF CD5+ CELLS
CO	NC2020/0006865	June 3, 2020	COMPOSITIONS AND METHODS FOR THE DEPLETION OF CD5+ CELLS
EA	202090947	May 14, 2020	COMPOSITIONS AND METHODS FOR THE DEPLETION OF CD5+ CELLS
EP	18883067.3	June 29, 2020	COMPOSITIONS AND METHODS FOR THE DEPLETION OF CD5+ CELLS
HK	62021027702.1	March 18, 2021	COMPOSITIONS AND METHODS FOR THE DEPLETION OF CD5+ CELLS
IL	274839	May 21, 2020	COMPOSITIONS AND METHODS FOR THE DEPLETION OF CD5+ CELLS
IN	202017023820	June 6, 2020	COMPOSITIONS AND METHODS FOR THE DEPLETION OF CD5+ CELLS
JP	2020-529433	May 29, 2020	COMPOSITIONS AND METHODS FOR THE DEPLETION OF CD5+ CELLS

Assignment A  
Magenta / HDPR

WBD (US) 61201731v1

Page 9 of 13  
v. 1.2  
Apr. 12 2023



**PATENT**  
**REEL: 064178 FRAME: 0222**

Country	Application No.	Filing Date	Title
Country	Application No.	Filing Date	Title
KR	10-2020-7018486	June 25, 2020	COMPOSITIONS AND METHODS FOR THE DEPLETION OF CD5+ CELLS
MX	MX/A/2020/004910	May 11, 2020	COMPOSITIONS AND METHODS FOR THE DEPLETION OF CD5+ CELLS
NZ	764422	May 18, 2020	COMPOSITIONS AND METHODS FOR THE DEPLETION OF CD5+ CELLS
SG	11202004294X	May 8, 2020	COMPOSITIONS AND METHODS FOR THE DEPLETION OF CD5+ CELLS
US	62/592,214	November 29, 2017	COMPOSITIONS AND METHODS FOR THE DEPLETION OF CD5+ CELLS
US	17/244,721	April 29, 2021	COMPOSITIONS AND METHODS FOR THE DEPLETION OF CD5+ CELLS
US	16/851,082	April 16, 2020	COMPOSITIONS AND METHODS FOR THE DEPLETION OF CD5+ CELLS
WO	PCT/US2018/063175	November 29, 2018	COMPOSITIONS AND METHODS FOR THE DEPLETION OF CD5+ CELLS
ZA	2020/02584	May 8, 2020	COMPOSITIONS AND METHODS FOR THE DEPLETION OF CD5+ CELLS



Assignment A Magenta / HDPR WBD (US) 61201731v1	Page 10 of 13 v. 1.2 Apr. 12 2023
---	---

Country	Application No.	Filing Date	Title
AU	2019311077	January 28, 2021	USE OF ANTI-CD5 ANTIBODY DRUG CONJUGATE (ADC) IN ALLOGENEIC CELL THERAPY
CA	3,107,383	January 21, 2021	USE OF ANTI-CD5 ANTIBODY DRUG CONJUGATE (ADC) IN ALLOGENEIC CELL THERAPY
CN	201980062065.X	March 22, 2021	USE OF ANTI-CD5 ANTIBODY DRUG CONJUGATE (ADC) IN ALLOGENEIC CELL THERAPY
EP	19842155.4	February 18, 2021	USE OF ANTI-CD5 ANTIBODY DRUG CONJUGATE (ADC) IN ALLOGENEIC CELL THERAPY
HK	62021043212.1	November 26, 2021	USE OF ANTI-CD5 ANTIBODY DRUG CONJUGATE (ADC) IN ALLOGENEIC CELL THERAPY
JP	2021-503594	January 21, 2021	USE OF ANTI-CD5 ANTIBODY DRUG CONJUGATE (ADC) IN ALLOGENEIC CELL THERAPY
US	17/155,832	January 22, 2021	USE OF ANTI-CD5 ANTIBODY DRUG CONJUGATE (ADC) IN ALLOGENEIC CELL THERAPY
US	62/702,296	July 23, 2018	USE OF ANTI-CD5 ANTIBODY DRUG CONJUGATE (ADC) IN ALLOGENEIC CELL THERAPY
US	62/773,047	November 29, 2018	USE OF ANTI-CD5 ANTIBODY DRUG CONJUGATE (ADC) IN ALLOGENEIC CELL THERAPY
WO	PCT/US2019/043125	July 23, 2019	USE OF ANTI-CD5 ANTIBODY DRUG CONJUGATE (ADC) IN ALLOGENEIC CELL THERAPY



Assignment A  
Magenta / HDPR

WBD (US) 61201731v1

Page 11 of 13  
v. 1.2  
Apr. 12 2023

**PATENT**  
**REEL: 064178 FRAME: 0224**

Country	Application No.	Filing Date	Title
AU	2020286508	December 8, 2021	T-CELL DEPLETING THERAPIES
CA	3,140,447	December 2, 2021	T-CELL DEPLETING THERAPIES
CN	202080055730.5	January 30, 2022	T-CELL DEPLETING THERAPIES
EP	20818567.8	December 13, 2021	T-CELL DEPLETING THERAPIES
JP	2021-572049	December 3, 2021	T-CELL DEPLETING THERAPIES
US	17/457,607	December 3, 2021	T-CELL DEPLETING THERAPIES
US	62/857,744	June 5, 2019	T-CELL DEPLETING THERAPIES
WO	PCT/US2020/036494	June 5, 2020	T-CELL DEPLETING THERAPIES

Country	Application No.	Filing Date	Title
US	16/858509	April 24, 2020	AMATOXIN ANTIBODY-DRUG CONJUGATES AND USES THEREOF



Assignment A Magenta / HDPR WBD (US) 61201731v1	Page 12 of 13 v. 1.2 Apr. 12 2023
---	---

**PATENT  
ASSIGNMENT**

WHEREAS, **Magenta Therapeutics, Inc.**, a Delaware corporation ("Assignor"), with principal offices located at 100 Technology Square (5th Floor), Cambridge, MA 02139, USA, is the owner of the patents described in the attached Schedule A ("Assigned Patents and Patent Applications"); and

WHEREAS, **Heidelberg Pharma Research GmbH**, a corporation organized under the laws of Germany ("Assignee"), with principal offices at Gregor-Mendel-Strasse 22, 68526 Ladenburg, Germany, is desirous of acquiring the Assigned Patents and Patent Applications;

NOW THEREFORE, for good and valuable consideration to the Assignors paid, the receipt and sufficiency of which is hereby acknowledged, the Assignor assigns to the Assignee, its successors and assigns, all right, title and interest in and to the Assigned Patents and Patent Applications together with the rights of recovery for past infringement thereof, including the right to sue for and collect damages for its own use, the same to be held and enjoyed by Assignee for its own use and benefit and the use and benefit of its successors and assigns, fully and entirely as the same would have been held and enjoyed by Assignor had this assignment not been made.

EXECUTED this 19 day of April 2023, at Cambridge, Massachusetts, USA.

**Magenta Therapeutics, Inc**

BY: Thomas Beetham

Name: Thomas Beetham  
Title: Chief Legal Officer

STATE of Massachusetts  
COUNTY OF Middlesex

The foregoing instrument was acknowledged before me this 19 day of April 2023, by Thomas Beetham, Chief Legal Officer (title) of **Magenta Therapeutics, Inc.**, a Delaware corporation, on behalf of the corporation. He is personally known to me.

Linsey George  
Notary Public, State of \_\_\_\_\_  
My commission \_\_\_\_\_

